TMDX
TransMedics Group, Inc.125.04
+1.89+1.53%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
4.27BP/E (TTM)
49.23Basic EPS (TTM)
2.54Dividend Yield
0%Recent Filings
10-Q
Q3 FY2025 results
TransMedics posted solid Q3 results, with total revenue hitting $143.8M, up 32% year-over-year and 15% quarter-over-quarter (derived), fueled by surging OCS Liver demand at $107.9M in the U.S. alone. Gross margin climbed to 59%, edging up from 56% last year, thanks to sharper NOP logistics. Operating income jumped to $23.3M from $3.9M, while diluted EPS rose to $0.66 from $0.12, reconciling cleanly with 40.7M shares including convertible notes. Cash swelled to $466.2M on $158.3M operating cash flow, minus $43.7M capex for aircraft; free cash flow stood at $114.6M (derived). Debt remains steady at $520M, with full covenant compliance. Yet regulatory shifts in organ procurement could crimp NOP growth.
8-K
Q3 revenue surges 32%
TransMedics reported third-quarter 2025 revenue of $143.8 million, up 32% from $108.8 million last year, driven by higher Organ Care System utilization in liver and heart transplants via its National OCS Program and expanded aviation fleet. Gross margin improved to 59% while operating expenses rose to $61.3 million amid R&D investments; net income hit $24.3 million. The company raised its full-year revenue guidance to $595–$605 million, targeting 10,000 U.S. NOP transplants by 2028. Yet risks like regulatory hurdles loom.
8-K
Aircraft fleet hits 22
TransMedics completed its latest aircraft acquisition on October 3, 2025, buying a fixed-wing plane from Teaghlach Aviation for $14.5 million, bringing the fleet to 22 dedicated to donor organ transport under the National OCS Program. This caps a series of related buys since 2023, bolstering logistics for organ preservation services. Fleet expansion sharpens delivery efficiency. Yet integration costs linger undisclosed.
8-K
Q2 revenue surges 38%
TransMedics reported Q2 2025 revenue of $157.4 million, up 38% from last year, driven by higher Organ Care System utilization in liver and heart transplants via the National OCS Program and aviation expansion. Net income hit $34.9 million, with gross margins steady at 61% despite rising R&D and operational investments. The company raised full-year revenue guidance to $585–$605 million. Strong execution fuels growth toward 10,000 U.S. NOP transplants by 2028.
10-Q
Q2 FY2025 results
TransMedics posted strong Q2 FY2025 results, with total revenue hitting $157.4 million, up 38% year-over-year from $114.3 million, fueled by robust U.S. OCS liver and heart transplant volumes alongside NOP service growth. Gross margin held steady at 61%, while operating income surged to $36.6 million from $12.5 million, driving diluted EPS to $0.92 on 40.6 million shares—reconciled via if-converted Notes impact. Cash swelled to $400.6 million, with free cash flow at $52.6 million (derived), against $510.9 million total debt including $460 million 1.50% convertible notes due 2028 and $60 million CIBC term loan at 6.3%. No material M&A, but Italy land purchase signals expansion. Revenue remains tied to unpredictable donor organ supply.
AEMD
Aethlon Medical, Inc.
2.94-0.11
BSX
Boston Scientific Corporation
92.95+0.76
MDT
Medtronic plc.
97.72-0.85
MDXG
MiMedx Group, Inc
7.25+0.13
RMD
ResMed Inc.
247.34-5.73
RMTG
Regenerative Medical Technology
0.04+0.00
SENS
Senseonics Holdings, Inc.
6.62-0.17
TCMD
Tactile Systems Technology, Inc
28.95+0.52
TELA
TELA Bio, Inc.
1.18+0.05
VMD
Viemed Healthcare, Inc.
7.26-0.11